- Home
- ACET vs IOBT Comparison
ACET vs IOBT Comparison
Compare ACET & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- IOBT
- Stock Information
- Founded
- ACET 1947
- IOBT 2014
- Country
- ACET United States
- IOBT Denmark
- Employees
- ACET N/A
- IOBT N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- IOBT Biotechnology: Pharmaceutical Preparations
- Sector
- ACET Health Care
- IOBT Health Care
- Exchange
- ACET Nasdaq
- IOBT Nasdaq
- Market Cap
- ACET 70.3M
- IOBT 57.9M
- IPO Year
- ACET N/A
- IOBT 2021
- Fundamental
- Price
- ACET $0.66
- IOBT $0.98
- Analyst Decision
- ACET Buy
- IOBT Strong Buy
- Analyst Count
- ACET 6
- IOBT 3
- Target Price
- ACET $6.00
- IOBT $9.33
- AVG Volume (30 Days)
- ACET 312.0K
- IOBT 220.8K
- Earning Date
- ACET 03-06-2025
- IOBT 05-13-2025
- Dividend Yield
- ACET N/A
- IOBT N/A
- EPS Growth
- ACET N/A
- IOBT N/A
- EPS
- ACET N/A
- IOBT N/A
- Revenue
- ACET N/A
- IOBT N/A
- Revenue This Year
- ACET N/A
- IOBT N/A
- Revenue Next Year
- ACET N/A
- IOBT N/A
- P/E Ratio
- ACET N/A
- IOBT N/A
- Revenue Growth
- ACET N/A
- IOBT N/A
- 52 Week Low
- ACET $0.67
- IOBT $0.66
- 52 Week High
- ACET $2.40
- IOBT $1.79
- Technical
- Relative Strength Index (RSI)
- ACET 34.86
- IOBT 48.39
- Support Level
- ACET $0.74
- IOBT $0.93
- Resistance Level
- ACET $0.91
- IOBT $1.24
- Average True Range (ATR)
- ACET 0.06
- IOBT 0.11
- MACD
- ACET -0.01
- IOBT -0.00
- Stochastic Oscillator
- ACET 4.82
- IOBT 24.51
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.